MX2022011431A - Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano. - Google Patents

Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano.

Info

Publication number
MX2022011431A
MX2022011431A MX2022011431A MX2022011431A MX2022011431A MX 2022011431 A MX2022011431 A MX 2022011431A MX 2022011431 A MX2022011431 A MX 2022011431A MX 2022011431 A MX2022011431 A MX 2022011431A MX 2022011431 A MX2022011431 A MX 2022011431A
Authority
MX
Mexico
Prior art keywords
compound
formula
methods
antibacterial agent
oxazolidinone compound
Prior art date
Application number
MX2022011431A
Other languages
English (en)
Inventor
Lihu Yang
Philippe Nantermet
Takao Suzuki
Brendan M Crowley
David B Olsen
Lanying You
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MX2022011431A publication Critical patent/MX2022011431A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere al compuesto de oxazolidinona de la Fórmula I: (ver Fórmula) (I) y sales farmacéuticamente aceptables del mismo. La presente invención también se refiere a composiciones que contienen el compuesto de la Fórmula I. La invención también proporciona métodos para inhibir el crecimiento de células micobacterianas así como un método para tratar infecciones por micobacterias por Mycobacterium tuberculosis al administrar una cantidad terapéuticamente eficaz de la Fórmula I y/o una sal farmacéuticamente aceptable del mismo, o una composición que comprende tal compuesto y/o sal.
MX2022011431A 2020-03-20 2021-03-17 Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano. MX2022011431A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2020/080359 WO2021184339A1 (en) 2020-03-20 2020-03-20 Oxazolidinone compound and methods of use thereof as an antibacterial agent
PCT/US2021/022652 WO2021188606A1 (en) 2020-03-20 2021-03-17 Oxazolidinone compound and methods of use thereof as an antibacterial agent

Publications (1)

Publication Number Publication Date
MX2022011431A true MX2022011431A (es) 2022-10-03

Family

ID=75478174

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011431A MX2022011431A (es) 2020-03-20 2021-03-17 Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano.

Country Status (22)

Country Link
US (1) US12435077B2 (es)
EP (1) EP4121058B1 (es)
JP (1) JP7241984B2 (es)
KR (1) KR102824010B1 (es)
CN (1) CN115605208A (es)
AR (1) AR121598A1 (es)
AU (1) AU2021239937B2 (es)
BR (1) BR112022018674A2 (es)
CA (1) CA3172304A1 (es)
CL (1) CL2022002511A1 (es)
CO (1) CO2022013595A2 (es)
CR (1) CR20220472A (es)
DK (1) DK4121058T3 (es)
EC (1) ECSP22073580A (es)
GE (2) GEP20247641B (es)
IL (1) IL296401A (es)
MX (1) MX2022011431A (es)
PE (1) PE20230002A1 (es)
PH (1) PH12022552495A1 (es)
TW (1) TWI799814B (es)
UA (1) UA130497C2 (es)
WO (2) WO2021184339A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021258013A1 (en) 2020-06-18 2021-12-23 Akagera Medicines, Inc. Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
WO2023102363A1 (en) * 2021-11-30 2023-06-08 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis
US20260062394A1 (en) * 2022-08-10 2026-03-05 Merck Sharp & Dohme Llc Processes for preparing oxazolidinone compounds

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
ATE146783T1 (de) 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
ATE209193T1 (de) 1996-04-11 2001-12-15 Upjohn Co Verfahren zur herstellung von oxazolidinonen
CA2288750A1 (en) 1997-05-30 1998-12-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
HUP0101958A3 (en) 1998-05-18 2003-07-28 Upjohn Co Enhancement oxazolidinone antibacterial agents activity by using arginine derivatives
JP2000204084A (ja) 1998-11-11 2000-07-25 Hokuriku Seiyaku Co Ltd チオカルバミド酸誘導体
EP1133493A1 (en) 1998-11-27 2001-09-19 PHARMACIA & UPJOHN COMPANY Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6297242B1 (en) 1999-08-12 2001-10-02 Ortho-Mcneil Pharmaceutical, Inc. N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof
HUP0203869A2 (hu) * 1999-12-21 2003-07-28 Pharmacia & Upjohn Co. Szulfoximin funkcionalitással rendelkező oxazolidinok és alkalmazásuk mikrobaellenes szerként, a vegyületeket tartalmazó gyógyszerkészítmények
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU2001253113B2 (en) 2000-04-20 2005-02-03 Pharmacia & Upjohn Company Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
JP2003535860A (ja) 2000-06-05 2003-12-02 ドン・ア・ファーム・カンパニー・リミテッド 新規なオキサゾリジノン誘導体及びその製造方法
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
WO2002002095A2 (en) 2000-06-30 2002-01-10 Pharmacia & Upjohn Company Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
US6696426B2 (en) 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
AU2002224421A1 (en) * 2000-10-17 2002-04-29 Pharmacia And Upjohn Company Methods of producing oxazolidinone compounds
MXPA03006958A (es) * 2001-02-05 2003-11-18 Upjohn Co Composicion para administracion rectal de farmaco antibacterial de oxazolidinona.
GB0108764D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compounds
NZ528996A (en) 2001-04-20 2006-01-27 Upjohn Co Process to prepare oxazolidinones
EP1379509A1 (en) 2001-04-20 2004-01-14 PHARMACIA & UPJOHN COMPANY A method for the preparation of oxazolidinones
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
CA2453182A1 (en) 2001-07-10 2003-01-23 Meredith L. Greene Crystalline thiazine oxazolidinones
JP2005520782A (ja) 2001-07-12 2005-07-14 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 向上した水溶解度を有するアミド含有化合物およびアミド含有化合物の水溶解度を向上させる方法
US20030069235A1 (en) 2001-09-14 2003-04-10 J. Greg Slatter Treatment for ocular infections
JP3778425B2 (ja) 2001-10-03 2006-05-24 日立金属株式会社 表示装置に用いられる電子部品用Ａｇ合金膜および表示装置に用いられる電子部品用Ａｇ合金膜形成用スパッタリングターゲット材
WO2003062231A1 (en) 2002-01-24 2003-07-31 Pharmacia & Upjohn Company Antimicrobial dihydrothiazine and dihydrothiopyran oxazolidinones
TW200302095A (en) 2002-01-25 2003-08-01 Upjohn Co Oxazolidinone cotherapy
MXPA04008173A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
WO2003072081A1 (en) 2002-02-22 2003-09-04 Pharmacia Corporation Ophthalmic formulation with gum system
US7473699B2 (en) 2002-02-28 2009-01-06 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents
WO2003093247A2 (en) 2002-04-30 2003-11-13 Orchid Chemicals & Pharmaceuticals Ltd Antibacterial agents
TW200403240A (en) 2002-06-28 2004-03-01 Upjohn Co Difluorothioacetamides of oxazolidinones as antibacterial agents
DE60304360T2 (de) 2002-08-12 2006-11-16 Pharmacia & Upjohn Co. Llc, Kalamazoo N-aryl-2-oxazolidinone und deren derivate
WO2004026848A1 (en) 2002-09-20 2004-04-01 Lupin Limited Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
JP2004203809A (ja) 2002-12-26 2004-07-22 Meiji Seika Kaisha Ltd 新規ビフェニル誘導体
US20040191326A1 (en) 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
CN1816545A (zh) 2003-07-02 2006-08-09 默克制药公司 环丙基取代的噁唑烷酮抗生素及其衍生物
ATE471937T1 (de) 2003-07-02 2010-07-15 Merck Sharp & Dohme Cyclopropylgruppensubstituierte oxazolidinonantibiotika und derivate davon
AU2004256085B2 (en) 2003-07-02 2007-12-06 Kyorin, Pharmaceutical Co., Ltd. Cyclopropyl Group Substituted Oxazolydinone Antibiotics and Derivatives Thereof
US7047020B2 (en) 2003-07-16 2006-05-16 Qualcomm Inc. Assistance techniques for subscriber units having positioning capabilities
JP2007503426A (ja) 2003-08-25 2007-02-22 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 新規な抗微生物性アリールオキサゾリジノン化合物
US7265140B2 (en) 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
EP1737850B1 (en) 2004-04-19 2007-10-03 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2005113520A1 (en) * 2004-05-20 2005-12-01 Pharmacia & Upjohn Company Llc Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents
US7429661B2 (en) 2004-07-20 2008-09-30 Symed Labs Limited Intermediates for linezolid and related compounds
JP2008508271A (ja) 2004-07-28 2008-03-21 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその化合物を製造および使用する方法
PE20060619A1 (es) 2004-07-29 2006-07-11 Ferrer Int Derivados de oxazolidinona como antibacterianos
EP1799677A1 (en) 2004-10-08 2007-06-27 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2006059221A2 (en) * 2004-12-03 2006-06-08 Pharmacia & Upjohn Company Llc Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents
WO2006079896A2 (en) * 2005-01-27 2006-08-03 Pharmacia & Upjohn Company Llc Stable polyol formulations of oxazolidinone antibacterial agents
WO2007023507A2 (en) 2005-06-20 2007-03-01 Wockhardt Limited Oxazolidinones bearing antimicrobial activity composition and methods of preparation
EP1745784A1 (en) 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2008070619A1 (en) 2006-12-04 2008-06-12 Auspex Pharmaceuticals, Inc. Deuterated oxazolidinones and their use as antibiotics
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
WO2009020616A1 (en) 2007-08-06 2009-02-12 Micurx Pharmaceuticals, Inc. Antimicrobial ortho-fluorophenyl oxazolidinones for treatment of bacterial infections
US8575337B2 (en) 2008-06-24 2013-11-05 Research Foundation Itsuu Laboratory Oxazolidinone derivative having fused ring
BRPI0918802A2 (pt) * 2008-09-03 2019-09-17 Pfizer uso de (s)-n-[[3-[3-fluoro-4-(4-tiomorfolinil)fenil]-2-oxo-5-oxazolidinil] metil] acetamida e composição farmacêutica
WO2010084514A2 (en) 2009-01-02 2010-07-29 Neuland Laboratories Ltd. A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
CN101993448A (zh) 2009-08-24 2011-03-30 上海柯盟医药技术有限公司 可用于治疗传染病的抗分枝杆菌的噁唑烷酮
EP2311457A1 (en) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Pharmaceutical compositions for treating infections with drug resistant mycobacteria
WO2012082992A1 (en) 2010-12-15 2012-06-21 Biovista, Inc. Compositions and methods for cancer treatment
KR101271224B1 (ko) 2011-07-05 2013-06-10 한국과학기술연구원 항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법
WO2017015106A1 (en) * 2015-07-17 2017-01-26 The Global Alliance For Tb Drug Development, Inc. Substituted phenyloxazolidinones for antimicrobial therapy
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
US11040025B2 (en) 2016-02-17 2021-06-22 The Johns Hopkins University Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
ITUA20161708A1 (it) 2016-02-25 2017-08-25 Riccardo Curto Sistema di parcheggio automatizzato
WO2018170664A1 (en) 2017-03-20 2018-09-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
GB201814487D0 (en) 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
EP3914587A4 (en) 2019-01-18 2022-11-23 Merck Sharp & Dohme LLC OXAZOLIDINONE COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS

Also Published As

Publication number Publication date
GEP20247641B (en) 2024-07-10
UA130497C2 (uk) 2026-03-04
PH12022552495A1 (en) 2024-03-25
CN115605208A (zh) 2023-01-13
TWI799814B (zh) 2023-04-21
NZ792402A (en) 2025-09-26
CA3172304A1 (en) 2021-09-23
ECSP22073580A (es) 2022-11-30
JP7241984B2 (ja) 2023-03-17
DK4121058T3 (da) 2026-03-02
CO2022013595A2 (es) 2023-02-16
KR102824010B1 (ko) 2025-06-20
CR20220472A (es) 2022-11-14
AR121598A1 (es) 2022-06-22
TW202200573A (zh) 2022-01-01
EP4121058A1 (en) 2023-01-25
IL296401A (en) 2022-11-01
WO2021184339A1 (en) 2021-09-23
EP4121058B1 (en) 2026-02-18
US12435077B2 (en) 2025-10-07
US20240208958A1 (en) 2024-06-27
BR112022018674A2 (pt) 2022-11-01
AU2021239937A1 (en) 2022-10-06
AU2021239937B2 (en) 2023-10-26
GEAP202416059A (en) 2024-02-26
JP2023507683A (ja) 2023-02-24
PE20230002A1 (es) 2023-01-05
CL2022002511A1 (es) 2023-03-24
WO2021188606A1 (en) 2021-09-23
KR20220156577A (ko) 2022-11-25

Similar Documents

Publication Publication Date Title
MX2022011431A (es) Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano.
EA200970535A1 (ru) Антибактериальные производные хинолина
MY143564A (en) Quinoline derivatives and their use as mycobacterial inhibitors
CR20240147A (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
NO20081008L (no) Antibakterielle kinolinderivater
EA200970534A1 (ru) Антибактериальные производные хинолина
MX2009013581A (es) Derivados de 4-(n-azacicloalquil)anilidas como moduladores del canal de potasio.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
JOP20210353A1 (ar) مركبات وطرق استخدامها كعوامل مضادة للجراثيم
MX2025007492A (es) Compuestos lipidicos y composiciones de nanoparticulas lipidicas
JO2725B1 (en) Quinoline antibacterial derivatives
WO2023150291A3 (en) Heterocyclic compounds and methods of use
EA200970536A1 (ru) Антибактериальные хинолиновые производные
UA101307C2 (ru) Антибактериальные производные хинолина
MX2024005063A (es) Inhibidores de espirotriciclo de ripk1 y metodos de uso de los mismos.
MX2023010797A (es) Profarmacos antivirales de entecavir (etv) y formulaciones de los mismos.
MX2024002892A (es) Azalidos inmunomoduladores.
JO3270B1 (ar) مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
NZ792402B2 (en) Oxazolidinone compound and methods of use thereof as an antibacterial agent
CR20230487A (es) Compuestos cíclicos y métodos de uso
WO2023245015A3 (en) Phenyl amide compounds and methods of use
WO2022112358A3 (en) Compounds for treating enveloped virus infections